Puma Biotechnology logo
Puma Biotechnology PBYI
$ 7.26 4.16%

Annual report 2025
added 02-26-2026

report update icon

Puma Biotechnology Financial Statements 2011-2026 | PBYI

Annual Financial Statements Puma Biotechnology

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

378 M 145 M 293 M 174 M 124 M 406 M 314 M 1.02 B 2.44 B 1.02 B 1.34 B 6.33 B 3.57 B 527 M -

Shares

50 M 48.6 M 47.1 M 44.7 M 40.6 M 39.6 M 38.8 M 37.9 M 37.2 M 33.3 M 32.1 M 30 M 28.7 M 21.7 M -

Historical Prices

7.56 2.98 6.21 3.9 3.04 10.3 8.75 20.4 98.8 30.7 78.4 189 104 18.8 -

Net Income

31.1 M 30.3 M 21.6 M 2 K -29.1 M -60 M -75.6 M -114 M -292 M -276 M -239 M -142 M -54.7 M -74.4 M -10.2 M

Revenue

228 M 230 M 236 M 228 M 253 M 225 M 272 M 251 M 27.7 M - - - - - -

Cost of Revenue

58.2 M 64.4 M 62.7 M 55.1 M 63.7 M 39.4 M 36.8 M 34.6 M 5.57 M - - - - - -

Gross Profit

- - - - - - 235 M 216 M 22.1 M - - - - - -

Operating Income

37.3 M 31 M 32.6 M 23.7 M 1.29 M -30.4 M -39 M -94.7 M -292 M -277 M -240 M -142 M -54.8 M -74.4 M -10.2 M

Interest Expense

1.03 M 862 K 759 K -28 K 12.8 M 14 M 15 M 11 M 720 K -373 K 25 K -14 K 2 K - -80 K

EBITDA

48.2 M 42.5 M 44.2 M 33.6 M 12.6 M -20.4 M -29.8 M -87.3 M -290 M -275 M -240 M -142 M -54.4 M -74.2 M -10.1 M

Operating Expenses

- - - - - - 273 M 311 M 315 M 277 M 240 M 142 M 54.8 M 74.4 M 10.2 M

General and Administrative Expenses

70.8 M 80.2 M 89.9 M 90 M 116 M 118 M 141 M 146 M 107 M 53.8 M 31.8 M 19.4 M 9.79 M 24.5 M 9.32 M

All numbers in USD currency

Quarterly Income Statement Puma Biotechnology

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

50.3 M 49.7 M 49.6 M 49.1 M 49 M 48.3 M 48.2 M 47.6 M 47.5 M 46.8 M 46.6 M 46.3 M 45.6 M 45.1 M 42.2 M 41.2 M 40.8 M 40.5 M 40.3 M 39.9 M 39.7 M 39.4 M 39.3 M 39 M 38.9 M 38.6 M 38.5 M 38.2 M 38 M 37.8 M 37.7 M 37.5 M 37.2 M 37 M 36.9 M 35.7 M 32.5 M 32.5 M 32.5 M 32.4 M 32.3 M 32.2 M 31.6 M 30.2 M 30.1 M 30.1 M 29.6 M 28.8 M 28.7 M 28.7 M 28.7 M 26.5 M 20 M 20 M 20 M 20 M 4 M 4 M 20 M

Net Income

8.84 M 5.86 M 2.97 M - 20.3 M -4.53 M -4.82 M - 5.8 M 2.13 M 1.4 M - -360 K 9.37 M -3.4 M - -44.7 M -5.11 M 16.5 M -15 M -31.5 M 3.4 M -16.9 M -11.2 M -16.9 M -37.4 M -10.1 M -30.7 M -14.2 M -44.3 M -24.3 M -64.1 M -77.2 M -77.8 M -72.9 M -72.7 M -65.8 M -66.6 M -71 M -61.7 M -60.4 M -64.7 M -52.5 M -47.5 M -35.8 M -38.8 M -19.8 M -15.9 M -54.7 M -54.7 M -54.7 M -21.9 M -74.4 M -74.4 M -74.4 M - -10.2 M -10.2 M -10.2 M

Revenue

54.5 M 52.4 M 46 M - 80.5 M 47.1 M 43.8 M - 56.1 M 54.6 M 52.8 M - 57.1 M 59.5 M 45.7 M - 46.2 M 53.4 M 98.2 M 52.6 M 50.8 M 70.6 M 51.2 M 62.9 M 56.4 M 53.9 M 99.1 M 71.1 M 62.6 M 50.8 M 66.5 M 21.6 M 6.08 M - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

12.2 M 12.3 M 10.6 M - 29.1 M 10.7 M 10.7 M - 13.3 M 11.9 M 13.2 M - 12.5 M 14.9 M 10.8 M - 10.3 M - 29.6 M - 9.94 M - - - - 9.32 M 7.98 M - 9.05 M 8.83 M 6.38 M - 1.53 M - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

9.57 M 6.64 M 3.98 M - 22.1 M -2.18 M -2.3 M - 8.58 M 4.89 M 4.36 M - 2.39 M 12.1 M -747 K - -8.95 M -16.6 M 20.1 M - -12.1 M 7.13 M -14.3 M - -14.4 M -25.8 M 9.85 M - -11.3 M -41.4 M -23.4 M - -77.4 M -78.2 M -73.2 M - -66 M -66.5 M -71.2 M - -60.7 M -64.9 M -52.6 M - -36 M -38.9 M -19.8 M - -14.3 M -12.7 M -11.8 M - -25.9 M -14.8 M -11.9 M - -334 K -34.3 K -3.94 K

Interest Expense

115 K 410 K 359 K - 347 K 156 K 91 K - 74 K 86 K 3.31 M - 2.95 M 2.7 M 2.66 M - 3.12 M 3.52 M 3.45 M - 3.63 M 3.78 M 3.07 M - 3.05 M 4.45 M 4.44 M - 3.5 M 2.59 M 1.08 M - -45 K -30 K -13 K - 4 K -376 K -8 K - -2 K 6 K 22 K - 4 K -5 K -21 K - 39 K -39 K 3 K - - - - - -13.5 K - -

EBITDA

9.67 M 6.74 M 6.78 M - 22.2 M -2.08 M 598 K - 8.68 M 4.99 M 7.24 M - 2.59 M 12.2 M 1.71 M - -627 K -16.4 M 23.1 M - -5.05 M 11.3 M -12.3 M - -8.27 M -21.5 M 12 M - -6 M -38.2 M -22.1 M - -76 M -77.6 M -72.9 M - -65.4 M -66 M -71 M - -60.2 M -64.5 M -52.4 M - -35.5 M -38.6 M -19.7 M - -14 M -12.5 M -11.7 M - -25.8 M -14.7 M -11.8 M - -334 K -34.1 K -3.94 K

Operating Expenses

- - - - - - - - - - - - - - - - - 70 M 78 M - 62.9 M 63.5 M 65.5 M - 70.8 M 79.7 M 89.2 M - 73.9 M 92.2 M 89.9 M - 83.5 M 78.2 M 73.2 M - 66 M 66.5 M 71.2 M - 60.7 M 64.9 M 52.6 M - 36 M 38.9 M 19.8 M - 14.3 M 12.7 M 11.8 M - 25.9 M 14.8 M 11.9 M - 334 K 34.3 K 3.94 K

General and Administrative Expenses

16.8 M 18 M 17.6 M - 16.8 M 25 M 21.8 M - 22.8 M 24.5 M 22.5 M - 24 M 20.6 M 20.4 M - 26.1 M 39.4 M 28.2 M - 29.6 M 29.3 M 30.9 M - 31.4 M 33.5 M 45.5 M - 28.5 M 40.1 M 36.6 M - 32.5 M 24.9 M 18.4 M - 14 M 12.3 M 11 M - 8.81 M 5.53 M 7.87 M - 3.87 M 3.9 M 3.52 M - 2.26 M 2.27 M 2.27 M - 8.09 M 1.77 M 1.28 M - 334 K 34.1 K 3.94 K

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Puma Biotechnology PBYI
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Puma Biotechnology plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Amgen Amgen
AMGN
$ 345.82 1.71 % $ 186 B usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 12.61 2.35 % $ 3.95 B usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
argenx SE argenx SE
ARGX
$ 776.24 1.41 % $ 25 B niderlandNiderland
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 24.35 4.64 % $ 3.1 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.44 5.51 % $ 383 M britainBritain
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.85 2.39 % $ 9.26 B australiaAustralia
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.74 6.42 % $ 17.2 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 91.34 1.92 % $ 27.2 B germanyGermany
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 4.63 1.87 % $ 767 M britainBritain
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Cabaletta Bio Cabaletta Bio
CABA
$ 3.09 0.65 % $ 310 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.07 1.32 % $ 6.68 B israelIsrael
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
Cerus Corporation Cerus Corporation
CERS
$ 1.94 5.43 % $ 370 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
- - $ 1.2 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 2.92 6.18 % $ 7.62 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
- - $ 2.18 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.68 0.6 % $ 197 M usaUSA